EBITDA

EBITDA up 17 per cent to Rs 87 crore on Year on Year (YoY) basis

Registered revenue of ₹522 crore up by 78 per cent; EBITDA up 57 per cent to ₹92 crore on Y-o-Y basis, profit after tax was at ₹66…

EBITDA for the year stood at Rs 60.43 crores, up by 21.3 per cent

The company reported net profit of Rs 69.36 crores for FY22 as against net profit of Rs 62.25 crores in the corresponding period…

YoY, EBITDA at Rs 193 crores, EBITDA margin at 19 per cent; PAT at Rs 111 crores

Basis the long-term outlook, the company's Board has recommended a dividend of 200 per cent

For the year ending March 22, the revenues grew by 23.4 per cent at Rs 1502.7 crores, as against Rs 1217.4 crores, same period…

EBITDA for Q1FY22 was reported at Rs 26.31 crores, a rise of 17.37 per cent as compared to EBITDA of Rs 22.42 crores in Q1FY21

Company recommends dividend of 15 per cent – Rs 1.5 per share for FY21

Consolidated net profit was at Rs 2203.08 million for the quarter ended March 31, 2019 Glenmark Pharmaceuticals, a research-led…